New Zealand Prime Minister Jacinda Ardern receiving her first Pfizer/BioNTech dose, June 18 (Alex Burton/NZ Herald via AP Images)

Covid-19 roundup: Af­ter win­ning an EUA, GSK and Vir are back with full da­ta on their mon­o­clon­al an­ti­body; New Zealand au­tho­rizes Pfiz­er/BioN­Tech vac­cine for kids as young as 12

A few weeks af­ter snag­ging an emer­gency use au­tho­riza­tion for their mon­o­clon­al an­ti­body sotro­vimab based on in­ter­im da­ta, GSK and Vir Biotech­nol­o­gy are back with con­fir­ma­to­ry re­sults to sup­port the drug’s use in non-hos­pi­tal­ized Covid-19 pa­tients.

Sotro­vimab re­duced hos­pi­tal­iza­tion of more than 24 hours or death by 79% at Day 29 com­pared to place­bo, the part­ners said on Mon­day. The pri­ma­ry analy­sis was based on 1,057 pa­tients with mild to mod­er­ate Covid-19.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.